NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
Clinical Trials
12 trialsNCT05065411 2024-02-26
VERU-024
Veru Inc.
Phase 3 Terminated
NCT04869943 2024-01-26
ARTEST
Veru Inc.
Phase 3 Terminated
NCT03220178 2022-01-06
PRECYCLE
Palleos Healthcare GmbH
Phase 4 Terminated
NCT01121549 2014-01-22
A Non-Interventional Study With AromasinĀ® As Adjuvant Treatment Of Invasive Early Breast Cancer
Pfizer
Terminated
NCT00776659 2013-11-19
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin
Pfizer
Terminated
NCT00793546 2012-11-05
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer
Pfizer
Phase 2 Terminated
NCT01239745 2012-10-31
AromasinĀ® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
Pfizer
Terminated
NCT01155063 2012-10-01
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
Pfizer
Terminated
NCT01305239 2012-04-10
ETAPE
Pfizer
Terminated
NCT00040014 2012-02-16
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women
Pfizer
Phase 2 Terminated
NCT00417885 2010-09-21
A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
Pfizer
Phase 1/2 Terminated